RNAi-MEDIATED INHIBITION OF SPLEEN TYROSINE KINASE-RELATED INFLAMMATORY CONDITIONS
AssigneeArrowhead Pharmaceuticals, Inc.
InventorsJohn M. Yanni, Jon E. Chatterton, Daniel A. Gamache, Steven T. Miller
Life of this patent
Estimating the term…
Abstract
RNA interference is provided for inhibition of spleen tyrosine kinase (Syk) mRNA expression, in particular, for treating patients having a Syk-related inflammatory condition or at risk of developing a Syk-related inflammatory condition such as allergic conjunctivitis, ocular inflammation, dermatitis, rhinitis, asthma, allergy, or mast-cell disease.
Claims20
A composition comprising an interfering RNA having a length of 19 to 49 nucleotides, and comprising a region of at least 13 contiguous nucleotides having at least 90% sequence complementarity to, or at least 90% sequence identity with, the penultimate 13 nucleotides of the 3′ end of any one of SEQ ID NO:44-47.
A method of attenuating expression of Syk mRNA of a subject, comprising:
- administering to the subject a composition comprising an effective amount of interfering RNA having a length of 19 to 49 nucleotides and a pharmaceutically acceptable carrier, wherein the interfering RNA comprises region of at least 13 contiguous nucleotides having at least 90% sequence complementarity to, or at least 90% sequence identity with, the penultimate 13 nucleotides of the 3′ end of any one of SEQ ID NO:44-47,
- wherein the expression of Syk mRNA is attenuated thereby.
A composition comprising an interfering RNA having a length of 19 to 49 nucleotides, and comprising a sense nucleotide strand, an antisense nucleotide strand, and a region of at least near-perfect contiguous complementarity of at least 19 nucleotides;
- wherein the antisense strand hybridizes under physiological conditions to a portion of mRNA selected from the group consisting of mRNA corresponding to SEQ ID NO:
- 1 comprising nucleotide 642, 1009, 1273, or 1533.
Dependencies are inferred from the claim text.